Company: BIVIW
Filing Date: 2025-08-04
Form Type: S-1/A
Source: 0001520138-25-000235
Chunk: 15

Company: BIOVIE INC.
Filing Date: 2025-08-04
Form: S-1/A
Chunk 15
---
 change in the par value per share. The Reverse Stock Split reduced the number of shares of Common Stock issuable upon the exercise or vesting of the Company’s outstanding stock options, restricted stock units and warrants in proportion to the ratio of the Reverse Stock Split and caused a proportionate increase in the exercise prices of such stock options and warrants. The Reverse Stock Split did not change the total number of authorized shares of Common Stock. No fractional shares were issued as a result of the Reverse Stock Split. Stockholders who otherwise were entitled to receive a fractional share in connection with the Reverse Stock Split received one full share of the post-reverse stock split Common Stock in lieu of such fractional share. Commencing on July 7, 2025, trading of our Common Stock continued on The Nasdaq Capital Market on a Reverse Stock Split-adjusted basis. Other than our historical financial statements and notes thereto included herein, and except where otherwise noted, all references to our Common Stock presented in this prospectus have been adjusted to give retroactive effect to the Reverse Stock Split. Risk Factor Summary Our business operations are subject to numerous risks, factors and uncertainties, including those outside of our control, which could cause our actual results to be harmed, including risks regarding the following: Risks Relating to Our Business and Industry

| · | If these third parties contractors do not successfully carry out their contractual duties or meet expected                            
 deadlines or do not successfully perform and comply with regulatory requirements, we may not be able to obtain regulatory approval of 
 or commercialize our product candidates.                                                                                              |

| · | Successful development of biopharmaceuticals is highly uncertain and is dependent on numerous factors, 
 many of which are beyond our control.                                                                  |

| · | The concentration of our assets within certain financial institutions could have a material adverse effect 
 on its business, financial condition and results of operations.                                            |

| · | We are currently subject to securities class action litigation and may be subject to similar or other 
 litigation in the future, which may have a material adverse effect on our business.                   |

| · | We have no products approved for commercial sale, have never generated any revenues, and may never achieve 
 revenues or profitability, which could cause us to cease operations.                                       |

| · | We are a development stage company with a limited operating history, making it difficult for you to evaluate 
 our business and your investment.                                                                            |

| · | If the FDA or comparable foreign regulatory authorities approve generic versions of any of our product                                      
 candidates that receive marketing approval